Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.
Actively Recruiting
Lymphedema is a chronic and progressive condition that causes swelling in the upper or lower limbs and affects millions of people. Currently, there are no effective drug treatments, and management mainly relies on compression therapy. This research aims to evaluate the potential benefits of glucagon-like peptide-1 receptor agonists GLP-1 RAs, which are commonly used for obesity and diabetes, for improving quality of life and clinical outcomes in lymphedema patients. The study addresses an important gap by providing prospective data on this treatment approach. Participants will receive GLP-1 RA treatment prescribed by their primary care provider for six months to assess its effects on lymphedema. The study is designed as a prospective, single-arm trial involving adults with unilateral upper or lower extremity lymphedema. Follow-up visits will occur at baseline, three months, and six months post-treatment to monitor progress. The study will collect data on limb volume, bioimpedance, compression use, and incidence of cellulitis alongside quality of life measures. During the study, participants will complete the Lymphedema Life Impact Scale LLIS to report their quality of life. Researchers will also measure limb volume, bioimpedance, body mass index BMI, compression use, and record any episodes of cellulitis. Safety will be monitored throughout, and serious adverse events will be reported promptly. The total participation period is 24 months, including follow-up and data analysis, to evaluate the treatments impact comprehensively.
Actively Recruiting
Researchers are conducting a pilot Type 1 Hybrid Effectiveness-Implementation Trial to evaluate a tailored lung screening intervention in patients at risk for lung cancer. The study focuses on using an Electronic Health Record-embedded Social Determinants of Health SDoH screening tool in the Emergency Department to identify eligible patients and increase lung cancer screening uptake. The trial aims to assess the reach and preliminary effectiveness of this intervention in comparison with enhanced usual care by examining factors such as health literacy, mistrust, stigma, fatalism, knowledge, and lung screening health beliefs. The study compares two groups one receiving LungTalk, a tailored, interactive educational program delivered via iPad that adapts content based on smoking status and perceived barriers and another receiving a non-tailored lung screening pamphlet emailed to patients along with patient navigation support. LungTalk includes audio, video, and animation to engage participants, while the pamphlet provides standard educational information about lung cancer risk and screening. Participants are identified through SDoH screening and receive tailored or standard educational materials accordingly. Participants aged 50 to 80 who currently smoke or quit within 15 years and have a 20 pack-year smoking history are involved. Researchers will measure lung cancer screening uptake and stage of adoption at 1 week, 1 month, and 6 months post-intervention. Additional assessments include health literacy, medical mistrust, stigma, perceived risk, benefits and barriers to screening, self-efficacy, knowledge, and fatalism at 1 week and 1 month. The study uses randomized methods and collects data from electronic health records to monitor outcomes and reach over the trial period.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are studying whether Tamsulosin can reduce the high rate of postoperative urinary retention POUR in older men undergoing thoracic cancer surgery. POUR is common, especially in older men with enlarged prostates, and can lead to infections, discomfort, longer hospital stays, and other complications. This early phase study aims to determine if taking Tamsulosin before surgery lowers the incidence of POUR and helps patients regain normal urinary function sooner. Participants will take Tamsulosin 0.4 mg daily for seven days before their planned thoracic oncological surgery. They will also record their medication use in a diary. On the day of surgery, they will take Tamsulosin with a sip of water. After surgery, bladder ultrasounds will measure urine volume and retention to assess POUR. Standard bladder care will be provided if spontaneous urination does not occur or if urine residual is high, following a specific management plan. During the study, researchers will monitor spontaneous urination within 6 to 8 hours after surgery, the time and volume of urination within 24 hours, and the amount of urine left in the bladder. They will also track how many participants need medical intervention due to inability to urinate. Monitoring will help assess Tamsulosins potential to prevent urinary retention after surgery. The study is expected to be completed by June 2027.
Actively Recruiting
This research aims to collect and analyze long-term data on the use of Stereotactic Radiosurgery SRS and Stereotactic Body Radiation Therapy SBRT in treating patients with life-threatening tumors and other medical conditions. The study is an international, multi-year observational registry designed to understand how these treatments are used and their outcomes in everyday clinical practice. It continues the work of a prior study focused on CyberKnife treatment and is sponsored by The Radiosurgery Society. Participants in this study include patients with various conditions considered treatable by SRS or SBRT. The study captures information such as patient characteristics, disease details, treatment plans, and outcomes. This data collection allows participating sites to track treatment effectiveness and share their experiences. The registry is maintained by Vision Tree, Inc., which ensures data security and compliance with privacy regulations. Both prospective and some retrospective patient data are included. During the study, participants treatment outcomes are monitored over time, including overall survival for up to five years and local or distant recurrence within one to five years. The registry allows detailed recording of outcomes specific to each condition treated. Patients provide consent to participate, and their data contributes to improving understanding of these advanced radiation therapies. The total duration of participation varies as the study is ongoing and collects long-term results.
Actively Recruiting
Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.
Actively Recruiting
Researchers are studying targeted genomic analysis of blood and tissue samples from patients with cancer, focusing on rare cancers with poor prognosis or limited treatment options. This observational research aims to identify genetic changes using genomic sequencing to help understand cancer development and to provide clinicians with mutation data that may guide treatment or referral to relevant studies. The study also collects clinical outcomes and tumor genome data for future analysis and cancer model development. The study involves analyzing previously collected tumor tissue samples using next-generation sequencing to detect mutations. Patients may also provide blood samples for analysis of circulating cell-free DNA and circulating tumor cells. These procedures support the identification of actionable mutations that may have available targeted therapies. The research includes correlative laboratory biomarker analysis. Participants are followed after study completion every 3 months for 2 years, then every 6 months for up to 15 years to monitor clinical outcomes and mutation frequencies. Researchers measure the frequency of specific mutations and the rate of actionable mutations in rare or poor prognosis cancers over this period. This long-term follow-up helps correlate genomic findings with patient outcomes and supports future research developments.
Actively Recruiting
Researchers are evaluating the effect of atezolizumab, alone or combined with recombinant human hyaluronidase, compared to standard observation in preventing the return of stage I non-small cell lung cancer NSCLC after complete surgical removal. This phase III trial focuses on patients who have undergone surgical resection and aims to see if these immunotherapies may better prevent cancer recurrence than usual monitoring. Atezolizumab is a monoclonal antibody that may help the immune system attack cancer cells, and the combination with hyaluronidase may improve drug absorption. Participants are randomly assigned to one of two groups. One group undergoes observation with regular CT scans and optional blood sample collection for one year. The other group receives atezolizumab intravenously or atezolizumab with hyaluronidase subcutaneously every three weeks for up to one year 17 cycles, alongside similar monitoring. After treatment, patients are followed up at 30 days atezolizumab group only, then every 6 months for 3 years, and annually for an additional 7 years, totaling 10 years of follow-up. During the study, participants will have regular CT scans and may provide blood samples to help assess their health and disease status. Researchers will monitor disease-free survival, overall survival, recurrence rates, and adverse events over up to 10 years. Safety and treatment effects will be closely observed throughout treatment and follow-up to understand long-term outcomes and potential benefits of the therapies compared to observation alone.